458 related articles for article (PubMed ID: 11773278)
1. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.
Nemeth JA; Yousif R; Herzog M; Che M; Upadhyay J; Shekarriz B; Bhagat S; Mullins C; Fridman R; Cher ML
J Natl Cancer Inst; 2002 Jan; 94(1):17-25. PubMed ID: 11773278
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue.
Dong Z; Bonfil RD; Chinni S; Deng X; Trindade Filho JC; Bernardo M; Vaishampayan U; Che M; Sloane BF; Sheng S; Fridman R; Cher ML
Am J Pathol; 2005 Apr; 166(4):1173-86. PubMed ID: 15793297
[TBL] [Abstract][Full Text] [Related]
3. Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein.
Li Y; Che M; Bhagat S; Ellis KL; Kucuk O; Doerge DR; Abrams J; Cher ML; Sarkar FH
Neoplasia; 2004; 6(4):354-63. PubMed ID: 15256057
[TBL] [Abstract][Full Text] [Related]
4. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
[TBL] [Abstract][Full Text] [Related]
5. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice.
Sledge GW; Qulali M; Goulet R; Bone EA; Fife R
J Natl Cancer Inst; 1995 Oct; 87(20):1546-50. PubMed ID: 7563189
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated expression of TIMP-1 and TIMP-2 in bone inhibits osteolytic degradation by human prostate cancer.
Deng X; He G; Levine A; Cao Y; Mullins C
Int J Cancer; 2008 Jan; 122(1):209-18. PubMed ID: 17847032
[TBL] [Abstract][Full Text] [Related]
7. Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice.
Winding B; NicAmhlaoibh R; Misander H; Høegh-Andersen P; Andersen TL; Holst-Hansen C; Heegaard AM; Foged NT; Brünner N; Delaissé JM
Clin Cancer Res; 2002 Jun; 8(6):1932-9. PubMed ID: 12060638
[TBL] [Abstract][Full Text] [Related]
8. Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat.
Holst-Hansen C; Low JA; Stephens RW; Johnson MD; Carmeliet P; Frandsen TL; Brünner N; Dickson RB
Breast Cancer Res Treat; 2001 Aug; 68(3):225-37. PubMed ID: 11727959
[TBL] [Abstract][Full Text] [Related]
9. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression.
Littlepage LE; Sternlicht MD; Rougier N; Phillips J; Gallo E; Yu Y; Williams K; Brenot A; Gordon JI; Werb Z
Cancer Res; 2010 Mar; 70(6):2224-34. PubMed ID: 20215503
[TBL] [Abstract][Full Text] [Related]
11. Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model.
Lein M; Jung K; Le DK; Hasan T; Ortel B; Borchert D; Winkelmann B; Schnorr D; Loenings SA
Prostate; 2000 May; 43(2):77-82. PubMed ID: 10754522
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
Della Porta P; Soeltl R; Krell HW; Collins K; O'Donoghue M; Schmitt M; Krüger A
Anticancer Res; 1999; 19(5B):3809-16. PubMed ID: 10628317
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation.
Chavey C; Mari B; Monthouel MN; Bonnafous S; Anglard P; Van Obberghen E; Tartare-Deckert S
J Biol Chem; 2003 Apr; 278(14):11888-96. PubMed ID: 12529376
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases.
Nemeth JA; Cher ML; Zhou Z; Mullins C; Bhagat S; Trikha M
Clin Exp Metastasis; 2003; 20(5):413-20. PubMed ID: 14524530
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats.
Aparicio T; Kermorgant S; Dessirier V; Lewin MJ; Lehy T
Carcinogenesis; 1999 Aug; 20(8):1445-51. PubMed ID: 10426790
[TBL] [Abstract][Full Text] [Related]
16. The matrix metalloproteinase inhibitor batimastat inhibits the lung colonisation of orthotopically implanted malignant pancreatic tumor cells in SCID mice.
Mirzaie M; Herse B; Oster O; Schöndube F
Swiss Surg; 2002; 8(4):165-70. PubMed ID: 12227109
[TBL] [Abstract][Full Text] [Related]
17. A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice.
Lee J; Weber M; Mejia S; Bone E; Watson P; Orr W
Eur J Cancer; 2001 Jan; 37(1):106-13. PubMed ID: 11165137
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis.
Singh AS; Macpherson GR; Price DK; Schimel D; Figg WD
Oncol Rep; 2006 Mar; 15(3):519-24. PubMed ID: 16465406
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer in bone: importance of context for inhibition of matrix metalloproteinases.
Bissell MJ; Le Beyec J; Anderson RL
J Natl Cancer Inst; 2002 Jan; 94(1):4-5. PubMed ID: 11773268
[No Abstract] [Full Text] [Related]
20. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
